Filing Flows › Precigen (PGEN) › R&D spending
Precigen (PGEN) R&D spending by quarter
Precigen's R&D spending was $6.6M in Q3 2026 (third quarter 2026), -9% from Q2 2026. Over the last 5 quarters it ranged from $5.6M (Q1 2026) to $11.5M (Q2 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $6.6M | -9% | — |
| Q2 2026 | $7.3M | +29% | -37% |
| Q1 2026 | $5.6M | -51% | -46% |
| Q2 2025 | $11.5M | +10% | — |
| Q1 2025 | $10.5M | — | — |
Q3 2026 at a glance
Precigen, Q3 2026: revenue $74.1M (25× year over year), operating margin 52.1%, net earnings $35.8M, operating cash flow $11.9M. The chart follows the revenue to costs, profit and cash.
Questions
What is Precigen's R&D spending?
Precigen's R&D spending was $6.6M in Q3 2026 (third quarter 2026), -9% from Q2 2026.
How has Precigen's R&D spending changed?
Over the last 5 quarters it ranged from $5.6M (Q1 2026) to $11.5M (Q2 2025).